All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-17T11:41:15.000Z

EHA 2019 | Combining IMiDs and BiTEs or CAR T to improve outcomes for patients with R/R AML

Featured
Jun 17, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Hee-Je Kim from The Catholic University of Korea, Seoul, KR, talks about combining immunomodulatory drugs (IMiDs) and bispecific T-cell engagers (BiTEs) or chimeric antigen receptor (CAR) T-cell therapy to improve outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

Hee-Je Kim stressed the importance of bi- and tri-specific therapies, many of which are under investigation in clinical trials. Importantly, it was noted that these therapies are not perfect yet, and are sometimes anergic to the tumor microenvironment. Therefore it is important to combine these therapies with checkpoint inhibitors, CAR NK-cells / CAR T-cells and other novel first-in-class agents. He concluded that in the near future, patients with AML will likely have more options for life-prolonging therapies.

Combining IMiDs and BiTEs or CAR T to improve outcomes for patients with R/R AML

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox